Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose ara-C: Research paper

Pierre Fenaux, Norbert Gattermann, John F. Seymour, Eva Hellström-Lindberg, Ghulam J. Mufti, Ulrich Duehrsen, Steven D. Gore, Fernando Ramos, Odile Beyne-Rauzy, Alan List, David McKenzie, Jay Backstrom, Charles L. Beach

Research output: Contribution to journalArticle

Abstract

In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

Original languageEnglish (US)
Pages (from-to)244-249
Number of pages6
JournalBritish Journal of Haematology
Volume149
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Cytarabine
Survival
Research
Refractory Anemia with Excess of Blasts
Erythrocyte Transfusion
Lymphocyte Activation
Random Allocation
Drug-Related Side Effects and Adverse Reactions
Cytogenetics
Hospitalization
Research Personnel
Drug Therapy
Therapeutics
Pharmaceutical Preparations

Keywords

  • Azacitidine
  • Higher-risk myelodysplastic syndromes
  • Low-dose cytarabine (ara-C)
  • Myelodysplastic syndromes
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes : Azacitidine compared with low dose ara-C: Research paper. / Fenaux, Pierre; Gattermann, Norbert; Seymour, John F.; Hellström-Lindberg, Eva; Mufti, Ghulam J.; Duehrsen, Ulrich; Gore, Steven D.; Ramos, Fernando; Beyne-Rauzy, Odile; List, Alan; McKenzie, David; Backstrom, Jay; Beach, Charles L.

In: British Journal of Haematology, Vol. 149, No. 2, 04.2010, p. 244-249.

Research output: Contribution to journalArticle

Fenaux, P, Gattermann, N, Seymour, JF, Hellström-Lindberg, E, Mufti, GJ, Duehrsen, U, Gore, SD, Ramos, F, Beyne-Rauzy, O, List, A, McKenzie, D, Backstrom, J & Beach, CL 2010, 'Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose ara-C: Research paper', British Journal of Haematology, vol. 149, no. 2, pp. 244-249. https://doi.org/10.1111/j.1365-2141.2010.08082.x
Fenaux, Pierre ; Gattermann, Norbert ; Seymour, John F. ; Hellström-Lindberg, Eva ; Mufti, Ghulam J. ; Duehrsen, Ulrich ; Gore, Steven D. ; Ramos, Fernando ; Beyne-Rauzy, Odile ; List, Alan ; McKenzie, David ; Backstrom, Jay ; Beach, Charles L. / Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes : Azacitidine compared with low dose ara-C: Research paper. In: British Journal of Haematology. 2010 ; Vol. 149, No. 2. pp. 244-249.
@article{4d8823ca620b43aaa7f3788828515e62,
title = "Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose ara-C: Research paper",
abstract = "In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.",
keywords = "Azacitidine, Higher-risk myelodysplastic syndromes, Low-dose cytarabine (ara-C), Myelodysplastic syndromes, Survival",
author = "Pierre Fenaux and Norbert Gattermann and Seymour, {John F.} and Eva Hellstr{\"o}m-Lindberg and Mufti, {Ghulam J.} and Ulrich Duehrsen and Gore, {Steven D.} and Fernando Ramos and Odile Beyne-Rauzy and Alan List and David McKenzie and Jay Backstrom and Beach, {Charles L.}",
year = "2010",
month = "4",
doi = "10.1111/j.1365-2141.2010.08082.x",
language = "English (US)",
volume = "149",
pages = "244--249",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes

T2 - Azacitidine compared with low dose ara-C: Research paper

AU - Fenaux, Pierre

AU - Gattermann, Norbert

AU - Seymour, John F.

AU - Hellström-Lindberg, Eva

AU - Mufti, Ghulam J.

AU - Duehrsen, Ulrich

AU - Gore, Steven D.

AU - Ramos, Fernando

AU - Beyne-Rauzy, Odile

AU - List, Alan

AU - McKenzie, David

AU - Backstrom, Jay

AU - Beach, Charles L.

PY - 2010/4

Y1 - 2010/4

N2 - In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

AB - In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

KW - Azacitidine

KW - Higher-risk myelodysplastic syndromes

KW - Low-dose cytarabine (ara-C)

KW - Myelodysplastic syndromes

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77949823230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949823230&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08082.x

DO - 10.1111/j.1365-2141.2010.08082.x

M3 - Article

C2 - 20136825

AN - SCOPUS:77949823230

VL - 149

SP - 244

EP - 249

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -